Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 23 | 2025 | 416 | 3.620 |
Why?
|
| Drug Eruptions | 2 | 2022 | 8 | 0.860 |
Why?
|
| Puerto Rico | 17 | 2023 | 1413 | 0.810 |
Why?
|
| Influenza, Human | 1 | 2023 | 92 | 0.740 |
Why?
|
| Hypersensitivity | 2 | 2019 | 32 | 0.690 |
Why?
|
| Angioedemas, Hereditary | 1 | 2020 | 1 | 0.660 |
Why?
|
| Otitis Externa | 1 | 2020 | 1 | 0.660 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2020 | 5 | 0.660 |
Why?
|
| Skin Tests | 1 | 2019 | 13 | 0.600 |
Why?
|
| Anesthetics | 1 | 2019 | 11 | 0.590 |
Why?
|
| Morpholines | 1 | 2019 | 72 | 0.580 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2025 | 64 | 0.560 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 1 | 0.550 |
Why?
|
| T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2017 | 1 | 0.550 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 10 | 0.540 |
Why?
|
| Dermatitis, Atopic | 1 | 2017 | 10 | 0.530 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 279 | 0.460 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2014 | 5 | 0.440 |
Why?
|
| Humans | 35 | 2025 | 43102 | 0.440 |
Why?
|
| Emergency Service, Hospital | 3 | 2023 | 278 | 0.430 |
Why?
|
| Anaphylaxis | 1 | 2013 | 15 | 0.410 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2025 | 44 | 0.400 |
Why?
|
| Mites | 1 | 2012 | 9 | 0.370 |
Why?
|
| Rhinitis | 1 | 2012 | 18 | 0.360 |
Why?
|
| Allergens | 1 | 2012 | 65 | 0.350 |
Why?
|
| Child | 14 | 2017 | 3443 | 0.340 |
Why?
|
| Allergy and Immunology | 1 | 2011 | 14 | 0.340 |
Why?
|
| Physician's Role | 1 | 2011 | 40 | 0.330 |
Why?
|
| Administration, Topical | 2 | 2020 | 39 | 0.310 |
Why?
|
| Adult | 17 | 2025 | 13872 | 0.300 |
Why?
|
| Immunoglobulin E | 5 | 2019 | 61 | 0.290 |
Why?
|
| Middle Aged | 10 | 2025 | 12222 | 0.290 |
Why?
|
| Mexican Americans | 7 | 2008 | 226 | 0.270 |
Why?
|
| Male | 20 | 2025 | 23409 | 0.250 |
Why?
|
| Female | 19 | 2025 | 24698 | 0.250 |
Why?
|
| United States | 7 | 2023 | 5205 | 0.240 |
Why?
|
| Bronchodilator Agents | 6 | 2007 | 26 | 0.220 |
Why?
|
| Child, Preschool | 3 | 2014 | 1546 | 0.210 |
Why?
|
| Immunization | 1 | 2023 | 94 | 0.200 |
Why?
|
| Hydroxyzine | 1 | 2022 | 2 | 0.200 |
Why?
|
| Patient Preference | 1 | 2023 | 60 | 0.190 |
Why?
|
| Adolescent | 12 | 2014 | 6081 | 0.190 |
Why?
|
| Beclomethasone | 1 | 2022 | 1 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2022 | 91 | 0.180 |
Why?
|
| Vaccination | 1 | 2023 | 355 | 0.170 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2020 | 1 | 0.170 |
Why?
|
| Blister | 1 | 2020 | 2 | 0.170 |
Why?
|
| Patch Tests | 1 | 2020 | 4 | 0.170 |
Why?
|
| Neomycin | 1 | 2020 | 4 | 0.170 |
Why?
|
| Health Personnel | 1 | 2023 | 277 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2014 | 3156 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 310 | 0.160 |
Why?
|
| Acetic Acid | 1 | 2020 | 19 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2023 | 2544 | 0.160 |
Why?
|
| Recurrence | 1 | 2020 | 152 | 0.160 |
Why?
|
| Tobacco Use Disorder | 1 | 2003 | 250 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2020 | 93 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 234 | 0.150 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2019 | 7 | 0.150 |
Why?
|
| Placebos | 1 | 2019 | 41 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2020 | 69 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2008 | 863 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 1604 | 0.150 |
Why?
|
| Aged | 5 | 2014 | 8214 | 0.140 |
Why?
|
| Double-Blind Method | 1 | 2019 | 317 | 0.140 |
Why?
|
| Mycobacterium avium Complex | 1 | 2017 | 2 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 17 | 0.140 |
Why?
|
| Young Adult | 3 | 2014 | 5080 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 201 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 238 | 0.130 |
Why?
|
| Tongue Diseases | 1 | 2016 | 2 | 0.130 |
Why?
|
| Angioedema | 1 | 2016 | 2 | 0.130 |
Why?
|
| Albuterol | 2 | 2007 | 7 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2003 | 590 | 0.120 |
Why?
|
| Pain | 1 | 2019 | 290 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2853 | 0.110 |
Why?
|
| Insect Bites and Stings | 1 | 2013 | 3 | 0.100 |
Why?
|
| Food Hypersensitivity | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hospitals, Veterans | 1 | 2013 | 15 | 0.100 |
Why?
|
| Epinephrine | 1 | 2013 | 36 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2013 | 21 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 432 | 0.100 |
Why?
|
| Administration, Inhalation | 2 | 2025 | 92 | 0.100 |
Why?
|
| Quality of Life | 3 | 2023 | 616 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2013 | 142 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2008 | 734 | 0.070 |
Why?
|
| Urticaria | 1 | 2008 | 5 | 0.070 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 86 | 0.070 |
Why?
|
| Receptors, Prostaglandin | 1 | 2006 | 7 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 73 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2008 | 256 | 0.060 |
Why?
|
| Animals | 2 | 2013 | 16992 | 0.060 |
Why?
|
| Genotype | 5 | 2005 | 800 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2005 | 121 | 0.060 |
Why?
|
| Mexico | 4 | 2007 | 298 | 0.060 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2005 | 53 | 0.060 |
Why?
|
| Absenteeism | 1 | 2004 | 14 | 0.050 |
Why?
|
| Social Class | 1 | 2006 | 291 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2008 | 561 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1234 | 0.050 |
Why?
|
| Africa | 1 | 2023 | 82 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 15 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 97 | 0.050 |
Why?
|
| Hospital Units | 1 | 2003 | 4 | 0.050 |
Why?
|
| Cetirizine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2022 | 5 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 136 | 0.050 |
Why?
|
| Forced Expiratory Volume | 3 | 2008 | 75 | 0.050 |
Why?
|
| Data Collection | 1 | 2003 | 210 | 0.050 |
Why?
|
| Urban Population | 1 | 2004 | 374 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2005 | 719 | 0.040 |
Why?
|
| Poverty | 1 | 2004 | 400 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2005 | 206 | 0.040 |
Why?
|
| Parents | 1 | 2004 | 370 | 0.040 |
Why?
|
| Prevalence | 1 | 2004 | 1612 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 234 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 375 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 780 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 259 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 223 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2008 | 1285 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 205 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 760 | 0.030 |
Why?
|
| Macroglossia | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 2016 | 5 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 113 | 0.030 |
Why?
|
| Haplotypes | 2 | 2006 | 197 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2005 | 150 | 0.030 |
Why?
|
| Respiratory Function Tests | 2 | 2004 | 61 | 0.030 |
Why?
|
| Alleles | 2 | 2005 | 352 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 667 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2006 | 1759 | 0.020 |
Why?
|
| Spirometry | 1 | 2008 | 40 | 0.020 |
Why?
|
| San Francisco | 1 | 2007 | 35 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2007 | 44 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 7 | 0.020 |
Why?
|
| New York City | 1 | 2007 | 288 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 199 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 2003 | 5 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 20 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 82 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 490 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 317 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 492 | 0.010 |
Why?
|
| Prognosis | 1 | 2003 | 861 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 1009 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2003 | 863 | 0.010 |
Why?
|